Further Upside For Selvita S.A. (WSE:SLV) Shares Could Introduce Price Risks After 27% Bounce
Nov 27
Have your own idea? Try our Stock Screener
Polish (WIG) Life Sciences Industry Analysis
UpdatedDec 25, 2025
DataAggregated Company Financials
Companies4
- 7D-1.2%
- 3M-0.5%
- 1Y-24.0%
- YTD-26.0%
Over the last 7 days, the Life Sciences industry has dropped 2.3%, driven by Selvita declining 4.2%. The industry has fallen 24% in the last year. As for the next few years, earnings are expected to grow by 43% per annum.
Industry Valuation and Performance
Has the Polish Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 25 Dec 2025 | zł1.4b | zł464.6m | -zł124,641,157.00 | n/a | -11x | 2.9x |
| Sat, 22 Nov 2025 | zł1.4b | zł504.3m | -zł114,462,820.00 | 1732.9x | -11.9x | 2.7x |
| Mon, 20 Oct 2025 | zł1.3b | zł507.6m | -zł114,663,001.00 | 1417.1x | -11.7x | 2.6x |
| Wed, 17 Sep 2025 | zł1.5b | zł460.9m | -zł129,094,851.00 | 37.8x | -11.3x | 3.2x |
| Fri, 15 Aug 2025 | zł1.5b | zł460.9m | -zł129,094,851.00 | 39.3x | -11.4x | 3.2x |
| Sun, 13 Jul 2025 | zł1.4b | zł461.1m | -zł128,888,382.00 | 34.4x | -10.9x | 3.1x |
| Tue, 10 Jun 2025 | zł1.3b | zł457.8m | -zł130,948,382.00 | n/a | -10.1x | 2.9x |
| Thu, 08 May 2025 | zł1.6b | zł452.3m | -zł123,092,243.00 | 49.3x | -12.8x | 3.5x |
| Sat, 05 Apr 2025 | zł1.4b | zł452.3m | -zł123,092,243.00 | 49.3x | -11.5x | 3.1x |
| Mon, 03 Mar 2025 | zł1.6b | zł427.2m | -zł63,400,243.00 | 15.7x | -24.8x | 3.7x |
| Wed, 29 Jan 2025 | zł1.8b | zł427.0m | -zł65,964,174.00 | 16.1x | -26.7x | 4.1x |
| Fri, 27 Dec 2024 | zł2.0b | zł427.0m | -zł65,964,174.00 | 16.5x | -30x | 4.6x |
| Sun, 24 Nov 2024 | zł2.2b | zł427.0m | -zł66,551,174.00 | 18.2x | -33.1x | 5.2x |
| Tue, 22 Oct 2024 | zł2.4b | zł413.2m | -zł64,500,689.00 | 23.5x | -37.9x | 5.9x |
| Thu, 19 Sep 2024 | zł2.5b | zł421.4m | -zł39,488,869.00 | 18.4x | -63.4x | 5.9x |
| Sat, 17 Aug 2024 | zł2.4b | zł413.4m | -zł36,839,029.00 | 16.9x | -65x | 5.8x |
| Mon, 15 Jul 2024 | zł2.5b | zł413.5m | -zł32,092,283.00 | 19.4x | -78.5x | 6.1x |
| Wed, 12 Jun 2024 | zł2.5b | zł413.5m | -zł32,092,283.00 | 18.3x | -77.2x | 6x |
| Fri, 10 May 2024 | zł2.5b | zł421.0m | -zł26,364,957.00 | 18.4x | -94.5x | 5.9x |
| Sun, 07 Apr 2024 | zł2.6b | zł421.0m | -zł26,364,957.00 | 17.9x | -98.9x | 6.2x |
| Tue, 05 Mar 2024 | zł2.5b | zł495.9m | -zł52,637,957.00 | 44.1x | -47.6x | 5.1x |
| Thu, 01 Feb 2024 | zł2.4b | zł495.2m | -zł50,454,191.00 | 44.6x | -47.7x | 4.9x |
| Sat, 30 Dec 2023 | zł2.5b | zł495.2m | -zł50,454,191.00 | 44.1x | -49.1x | 5x |
| Mon, 27 Nov 2023 | zł2.6b | zł484.4m | -zł46,593,727.00 | 51.2x | -55.4x | 5.3x |
| Wed, 25 Oct 2023 | zł2.8b | zł512.0m | -zł37,354,934.00 | 32.5x | -74.2x | 5.4x |
| Fri, 22 Sep 2023 | zł2.8b | zł515.2m | -zł42,853,934.00 | 40.6x | -65.5x | 5.4x |
| Sun, 20 Aug 2023 | zł2.7b | zł508.2m | -zł60,736,048.00 | 44.5x | -45.3x | 5.4x |
| Tue, 18 Jul 2023 | zł2.8b | zł512.4m | -zł61,559,268.00 | 45.3x | -46.1x | 5.5x |
| Thu, 15 Jun 2023 | zł2.8b | zł512.4m | -zł61,559,268.00 | 43.9x | -45.3x | 5.4x |
| Sat, 13 May 2023 | zł2.8b | zł505.4m | -zł64,921,034.00 | 71.4x | -43.8x | 5.6x |
| Mon, 10 Apr 2023 | zł2.8b | zł489.1m | -zł73,305,590.00 | 68.4x | -38.2x | 5.7x |
| Wed, 08 Mar 2023 | zł3.2b | zł473.8m | -zł77,860,781.00 | 81.9x | -41.1x | 6.8x |
| Fri, 03 Feb 2023 | zł2.9b | zł483.0m | -zł79,277,613.00 | 60.6x | -37x | 6.1x |
| Sun, 01 Jan 2023 | zł2.8b | zł470.4m | -zł90,293,852.00 | 59.1x | -31.3x | 6x |
Price to Earnings Ratio
-31.3x
Current Industry PE
- Investors are pessimistic on the Polish Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 4.9x is higher than the industry's current PS ratio of 2.9x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have deteriorated over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the Polish Healthcare industry?
| PL Market | 1.59% | |
| Healthcare | 1.88% | |
| Life Sciences | -1.22% | |
| Clinical Research and Equipment | -1.22% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| RVU Ryvu Therapeutics | zł25.35 | 0.2% +zł1.2m | -35.0% | PS6.5x | |
| MDB Medicofarma Biotech | zł0.44 | 0.7% +zł203.9k | 21.9% | PS106x |